Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27235615.
- Also identified by DOI 10.1016/j.mcna.2016.03.006 and PMC identifier 5639879.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article reviews current pharmacologic treatment options for 3 common men's health concerns: hypogonadism, erectile dysfunction (ED), and benign prostatic hyperplasia (BPH). Specific topics addressed include: management of male hypogonadism using testosterone replacement therapy, use of oral phosphodiesterase inhibitors as first-line therapy for men with ED and the utility of intraurethral and intrapenile alprostadil injections for patients who do not respond to oral medications, and the role of alpha1-adrenergic antagonists, 5-alpha-reductase inhibitors, anticholinergic agents, and herbal therapies in the management of BPH.
Medical subject headings
- 5-alpha Reductase Inhibitors
- Erectile Dysfunction
- Hypogonadism
- Phosphodiesterase Inhibitors
- Prostatic Hyperplasia
- Testosterone